TRex Bio, Inc. Form SCHEDULE 13D — Oct 16, 2026
SV Biotech Crossover Opportunities Fund LP and its general partner SV BCO I GP LLP filed a Schedule 13D disclosing beneficial ownership of 1,920,667 shares of TRex Bio common stock, approximately 7.0% of the 27,445,682 shares outstanding after the company's October 13, 2026 IPO closing. The stake consists of 957,143 shares purchased in the IPO at $14.00 per share for $13,400,002, plus 963,524 shares issued on conversion of pre-IPO preferred stock at closing.
Key figures
- Shares Outstanding
- 27445682
- Lockup Days
- 180
- Percent Owned
- 7.0%
- Ipo Price Per Share
- 14
- Ipo Purchase Amount
- 13400002
- Ipo Shares Purchased
- 957143
- Shares Beneficially Owned
- 1920667
- Converted Preferred Shares
- 963524
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.